As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.
27 Analysts have issued a BioNTech SE - ADR forecast:
27 Analysts have issued a BioNTech SE - ADR forecast:
Jun '25 |
+/-
%
|
||
Revenue | 3,357 3,357 |
7%
7%
|
|
Gross Profit | 2,825 2,825 |
6%
6%
|
|
EBITDA | -456 -456 |
25%
25%
|
EBIT (Operating Income) EBIT | -811 -811 |
5%
5%
|
Net Profit | -403 -403 |
32%
32%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.
Head office | Germany |
CEO | Ugur Sahin |
Employees | 6,772 |
Founded | 2008 |
Website | www.biontech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.